Human Papilloma Virus, Juvenile Laryngeal Papilloma, Laryngeal Papilloma, Recurrent, Recurrent Respiratory Papillomatosis, Respiratory Papillomatosis
Conditions
Keywords
PD-L1 Expression, Human Papilloma Virus (HPV), Juvenile-onset Disease, Papillomatous Lesions, Monoclonal Antibody
Brief summary
Background: Recurrent respiratory papillomatosis (RRP) is a rare disease caused by human papillomavirus. It can cause voice changes, airway compromise, pulmonary lesions, and cancers. Programmed death-ligand 1 (PD-L1) is a protein on cells. It may be able to stop or decrease the immune system s response to viruses such as human papillomavirus. The drug Avelumab interferes with the activity of PD-L1. Researchers want to see if Avelumab treats RRP and study its side effects. Objective: To see if Avelumab works in treating RRP and is safe. Eligibility: People ages 18 and older with aggressive RRP that has not responded to available treatments Design: Participants will be screened with: Medical history Previously collected tumor tissue Physical exam Blood, urine, and heart tests Endoscopy procedure: A small tube with a camera is used to look in the nose, throat, larynx, and upper windpipe. Before starting treatment, participants will have: Endoscopy under anesthesia. A sample of papilloma will be taken. Voice handicap questionnaire Computed tomography (CT) scans Apheresis: An intravenous (IV) is inserted into an arm vein. White blood cells are separated from the rest of the blood and stored for research. The rest of the blood is returned through the same IV or one in the other arm. Participants will get the study drug by IV every 2 weeks for up to 12 weeks. Participants will repeat the previous tests throughout the study. If they respond to treatment, participants will be evaluated every 6 weeks (3 times), then every 12 weeks (3 times), then every 26 weeks (2 times) until their disease progresses. Participants will be evaluated 30 days after their last infusion. They will then be contacted annually.
Detailed description
Background * Recurrent respiratory papillomatosis (RRP) is a rare papillomatous disease of the aerodigestive tract that is caused by the Human Papilloma Virus (HPV). * RRP can progress to cause airway compromise, fatal pulmonary lesions, and invasive cancers. * There is no effective systemic therapy for RRP. Patients require repeated interventional procedures for disease control. * Study of a small number of RRP samples has shown programmed death-ligand 1 (PD-L1) expression by inflammatory mononuclear cells and by papilloma epithelial cells. * This clinical trial will evaluate the activity of a PD-L1-targeted drug, avelumab, in the treatment of RRP. This drug was selected for its demonstrated activity in a variety of cancers and for its acceptable safety profile. Objective -Determine the complete response rate for avelumab in the treatment of patients with RRP. Eligibility * Histologically confirmed diagnosis of RRP. * One of the following: * A Derkay anatomic score of 10 or greater and a history of two or more endoscopic interventions in the last 12 months for control of RRP. * Pulmonary RRP with pulmonary disease that is measurable by computed tomography scan. * Tracheal involvement with RRP that has required either two or more endoscopic interventions in the last 12 months or a tracheostomy. * Age 18 years or greater. * Eastern Oncology Cooperative Group Performance Score of 0 or 1. Design * Phase II clinical trial * Simon optimal two-stage design with initial enrollment of 12 patients and expansion to 37 patients if one or more complete response(s) is/are observed in the initial patients.
Interventions
DRUGAvelumab
Avelumab 10 mg/kg intravenous (IV) every 2 weeks for up to 6 doses.
Sponsors
National Cancer Institute (NCI)
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 99 Years
Healthy volunteers
No
Inclusion criteria
* INCLUSION CRITERIA: Recurrent Respiratory Papillomatosis (RRP) CRITERIA: * Histological diagnosis of RRP confirmed by pathology report from a Clinical Laboratory Improvement Amendments (CLIA)-certified laboratory. -One of the following: * A Derkay anatomic score of 10 or greater and a history of two or more endoscopic interventions in the last 12 months for control of RRP. * Pulmonary RRP with pulmonary disease that is measurable by computed tomography scan. * Tracheal involvement with RRP that has required either two or more endoscopic interventions in the last 12 months or a tracheostomy. * Greater than or equal to 18 years of age. * Able to understand and sign the Informed Consent Document. * Clinical performance status of Eastern Cooperative Oncology Group (ECOG) 0 or 1. * Willing to undergo endoscopic evaluation with biopsies in compliance with this protocol. * No systemic therapy for RRP for four weeks prior to treatment. * Screening laboratory values must meet the following criteria and should be obtained within 14 days prior to first dose: * White blood cells (WBC) \> 2000/microL * Neutrophils \> 1500/microL * Platelets \> 100 times10(3)/microL * Hemoglobin \> 9.0 g/dL * Serum creatinine \< 1.5 times upper limit of normal (ULN) or creatinine clearance (CrCl) \> 30 mL/min (measured or calculated using the Cockcroft-Gault formula below): * Female CrCl: (140 - age in years) times weight in kg x 0.85/72 times serum creatinine in mg/dL * Male CrCl: (140 - age in years) times weight in kg x 1.00/72 times serum creatinine in mg/Dl * Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) less than or equal to 2.5 times ULN; for subjects with documented metastatic disease to theliver, AST and ALT levels less than or equal to 5 times ULN * Total Bilirubin less than or equal to 1.5 times ULN * Sexually active subjects (men and women) and all subjects of reproductive potential must agree to use two methods of contraception: one highly effective and one other effective method for at least 28 days prior, throughout the avelumab treatment and for at least 60 days after avelumab treatment. Highly Effective Methods are defined as: Intrauterine device (IUD), hormonal (birth control pills, injections, implants), tubal ligation and partners vasectomy; Other Effective Methods are defined as: latex condom, diaphragm and cervical cap. * Seronegative for human immunodeficiency virus (HIV) antibody. The experimental treatment being evaluated in this protocol depends on an intact immune system. Patients who are HIV seropositive can have decreased immune function and thus are likely less responsive to the experimental treatment. * Seronegative for hepatitis B antigen, positive hepatitis B tests can be further evaluated by confirmatory tests (Hep B deoxyribonucleic acid (DNA) Quantification (Quant), HBV Viral Load), and if confirmatory tests are negative, the patient can be enrolled. * Seronegative for hepatitis C antibody unless antigen negative. If hepatitis C antibody test is positive, then patients must be tested for the presence of antigen by Hep C RNA Quant, Hepatitis C Virus (HCV) Viral Load and be HCV ribonucleic acid (RNA) negative.
Exclusion criteria
* Any severe acute or chronic medical or psychiatric conditions including recent (within the past year) or active suicidal ideation or behavior; liver, lung disease (with the exception of what is specified in inclusion criteria above), or laboratory abnormalities that, in the opinion of the investigators, may increase the risk associated with study participation or study drug administration, impair the ability of the subject to receive protocol therapy, or interfere with the interpretation of study results and in the judgment of the investigator, would make the patient inappropriate for entry into this study. Patients with mild to moderate asthma or chronic obstructive pulmonary disease (COPD) well controlled with oral or inhaled medications are permitted to enroll. * Subjects with active, known or suspected autoimmune disease. Subjects with vitiligo, residual hypothyroidism due to autoimmune condition only requiring hormone replacement, or psoriasis not requiring systemic treatment, are permitted to enroll. * Subjects with a condition requiring systemic treatment with either corticosteroids (\> 10 mg daily prednisone equivalents) or other immunosuppressive medications within 14 days of study drug administration. Inhaled, topical intranasal or intro-ocular steroids, and adrenal replacement doses \<10 mg daily prednisone equivalents are permitted in the absence of active autoimmune disease. * Prior organ transplantation, including allogeneic stem cell transplantation. * Prior treatment with an anti-programmed death-ligand 1 (PD-1), anti-PD-L1, anti-programmed death-ligand 2 (PD-L2), anti-cytotoxic T-lymphocyte associated protein 4 (CTLA-4) antibody, or any other antibody or drug specifically targeting T-cell co-stimulation or immune checkpoint pathways. * Patients who are receiving any other investigational agents * Pregnant or breast feeding. Women of childbearing potential must have a negative pregnancy test at screening. Women of childbearing potential include women who have experienced menarche and who have not undergone successful surgical sterilization (hysterectomy, bilateral tubal ligation, or bilateral oophorectomy) or are not postmenopausal. Post-menopause is defined as amenorrhea greater than or equal to 12 consecutive months. Note: women who have been amenorrheic for 12 or more months are still considered to be of childbearing potential if the amenorrhea is possibly due to prior chemotherapy, anti-estrogens, ovarian suppression or any other reversible reason. * History of allergy to study drug components. History of severe hypersensitivity reaction to any monoclonal antibody (Grade greater than or equal to 3 National Cancer Institute (NCI)-Common Terminology Criteria in Adverse Events (CTCAE) v 4.03), any history of anaphylaxis, or uncontrolled asthma (that is, 3 or more features of partially controlled asthma). * Clinically significant (i.e., active) cardiovascular disease: cerebral vascular accident/stroke (\< 6 months prior to enrollment), myocardial infarction (\< 6 months prior to enrollment), unstable angina, congestive heart failure (greater than or equal to New York Heart Association Classification Class II), or serious cardiac arrhythmia requiring medication. * Persisting toxicity related to prior therapy of Grade \>1 NCI-CTCAE v 4.03; however, alopecia, sensory neuropathy Grade less than or equal to 2 or other Grade less than or equal to 2 adverse events (AEs) not constituting a safety risk based on investigator's judgment are acceptable. * Known alcohol or drug abuse. * Vaccination within 4 weeks of the first dose of avelumab and while on trial is prohibited except for administration of inactivated vaccines.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of Patients With Laryngotracheal Recurrent Respiratory Papillomatosis (RPP) Who Achieve a Complete Response With Avelumab as Measured by Derkay Score Calculated From Clinical Endoscopy | Disease response was performed at 6 and 12 weeks after the first dose of Avelumab. Patients who experience a complete response will be evaluated every 6 weeks x 3, then every 12 weeks x 3, then every 26 weeks x 2 or until disease progression,up to 3 years | The Derkay is an objective score based on the number of sites and bulkiness of papillomas within the pharynx, larynx and trachea and a subjective score determined by voice and treating symptoms. Complete response is assessed by The Derkay Staging System which is defined as a physical exam and/or clinic-based flexible nasopharyngolaryngoscopy and/or tracheoscopy, exam under anesthesia with endoscopy and biopsies; no evidence of papillomas on physical exam and/or clinic based flexible nasopharyngolaryngoscopy and/or tracheoscopy; and no evidence of papillomas by exam under anesthesia (sedation or general anesthesia) with endoscopy and biopsies. |
| Number of Patients With Pulmonary Recurrent Respiratory Papillomatosis (RPP) Who Achieve a Complete Response With Avelumab as Measured by the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 Calculated From Chest Computed Tomography (CT) Scans | Disease response was performed at 6 and 12 weeks after the first dose of Avelumab. Patients who experience a complete response will be evaluated every 6 weeks x 3, then every 12 weeks x 3, then every 26 weeks x 2 or until disease progression,up to 3 years | Complete response is measured by The Response Criteria in Solid Tumors (RECIST) v1.1 calculated from chest CT scans. Complete response is absence of disease (e.g., lesions) by imaging. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Number of Patients With Pulmonary Recurrent Respiratory Papillomatosis (RPP) Who Achieve a Partial Response With Avelumab as Measured by the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 Calculated From Chest Computed Tomography (CT) Scans | Disease response was performed at 6 and 12 weeks after the first dose of Avelumab. Patients who experience a complete response will be evaluated every 6 weeks x 3, then every 12 weeks x 3, then every 26 weeks x 2 or until disease progression, up to 3 year | Partial response assessed by imaging using RECIST v1.1. is defined as a ≥ 30% decrease in the sum of the longest diameters of target lesions compared with baseline. |
| Effect of Treatment With Avelumab on Voice Handicap Index-10 Score | Baseline, 6 weeks, and 12 weeks after the first dose of Avelumab. | The Voice Handicap Index-10 questionnaire (as measured by derkay score) consists of 10 questions and determines whether a participant has a voice handicap. The scoring options for each question range from 0 (for never) to 4 (for always). The total scores (combined value from all 10 questions) range from 0 - 40. Higher scores represent a worse voice handicap. Lower scores represent a less voice handicap. |
| Number of Participants With Serious and Non-serious Adverse Events | Date treatment consent signed to date off study, approximately 28 months and 20 days. | Here is the count of participants with serious and non-serious adverse events assessed by the Common Terminology Criteria in Adverse Events (CTCAE v4.0). A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned. |
| Duration of Clinical Responses to Avelumab | Disease response was performed at 6 and 12 weeks after the first dose of Avelumab. Patients who experience a complete response will be evaluated every 6 weeks x 3, then every 12 weeks x 3, then every 26 weeks x 2 or until disease progression,up to 4.5 yrs | The duration of clinical responses to Avelumab is calculated from the protocol end of treatment endoscopic debulking to the next clinically indicated endoscopic debulking procedure. |
| Number of Patients With Laryngotracheal Recurrent Respiratory Papillomatosis (RPP) Who Achieve a Partial Response With Avelumab as Measured by Derkay Score Calculated From Clinical Endoscopy | Disease response was performed at 6 and 12 weeks after the first dose of Avelumab. Patients who experience a complete response will be evaluated every 6 weeks x 3, then every 12 weeks x 3, then every 26 weeks x 2 or until disease progression,up to 3 years | Partial response is assessed by flexible nasopharyngolaryngoscopy and/or tracheoscopy using the Derkay staging system if the patient does not have pulmonary disease. The Derkay is an objective score based on the number of sites and bulkiness of papillomas within the pharynx, larynx and trachea and a subjective score determined by voice and treating symptoms. Partial response is a decrease in Derkay anatomic score of 30% or greater. |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Avelumab Avelumab 10 mg/kg intravenous (IV) every 2 weeks for up to 6 doses.
Avelumab: Avelumab 10 mg/kg intravenous (IV) every 2 weeks for up to 6 doses. | 13 |
| Total | 13 |
Withdrawals & dropouts
| Period | Reason | FG000 |
|---|---|---|
| Overall Study | PI discretion/off study prior to trtmt | 1 |
Baseline characteristics
| Characteristic | Avelumab |
|---|---|
| Age, Categorical <=18 years | 0 Participants |
| Age, Categorical >=65 years | 0 Participants |
| Age, Categorical Between 18 and 65 years | 13 Participants |
| Age, Continuous | 46.95 years STANDARD_DEVIATION 15.83 |
| Ethnicity (NIH/OMB) Hispanic or Latino | 1 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 12 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 0 Participants |
| Patients Who Had Repeated Endoscopic Debulking to Remove Paillomatosis Lesions Prior to Treatment | 13 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants |
| Race (NIH/OMB) Asian | 2 Participants |
| Race (NIH/OMB) Black or African American | 0 Participants |
| Race (NIH/OMB) More than one race | 1 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants |
| Race (NIH/OMB) White | 10 Participants |
| Region of Enrollment United States | 13 Participants |
| Sex: Female, Male Female | 6 Participants |
| Sex: Female, Male Male | 7 Participants |
Adverse events
| Event type | EG000 affected / at risk |
|---|---|
| deaths Total, all-cause mortality | 0 / 13 |
| other Total, other adverse events | 13 / 13 |
| serious Total, serious adverse events | 2 / 13 |
Outcome results
Primary
Number of Patients With Laryngotracheal Recurrent Respiratory Papillomatosis (RPP) Who Achieve a Complete Response With Avelumab as Measured by Derkay Score Calculated From Clinical Endoscopy
The Derkay is an objective score based on the number of sites and bulkiness of papillomas within the pharynx, larynx and trachea and a subjective score determined by voice and treating symptoms. Complete response is assessed by The Derkay Staging System which is defined as a physical exam and/or clinic-based flexible nasopharyngolaryngoscopy and/or tracheoscopy, exam under anesthesia with endoscopy and biopsies; no evidence of papillomas on physical exam and/or clinic based flexible nasopharyngolaryngoscopy and/or tracheoscopy; and no evidence of papillomas by exam under anesthesia (sedation or general anesthesia) with endoscopy and biopsies.
Time frame: Disease response was performed at 6 and 12 weeks after the first dose of Avelumab. Patients who experience a complete response will be evaluated every 6 weeks x 3, then every 12 weeks x 3, then every 26 weeks x 2 or until disease progression,up to 3 years
Population: Nine of twelve patients had evaluable laryngotracheal disease as assessed by clinical endoscopy.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Avelumab | Number of Patients With Laryngotracheal Recurrent Respiratory Papillomatosis (RPP) Who Achieve a Complete Response With Avelumab as Measured by Derkay Score Calculated From Clinical Endoscopy | 0 Participants |
Primary
Number of Patients With Pulmonary Recurrent Respiratory Papillomatosis (RPP) Who Achieve a Complete Response With Avelumab as Measured by the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 Calculated From Chest Computed Tomography (CT) Scans
Complete response is measured by The Response Criteria in Solid Tumors (RECIST) v1.1 calculated from chest CT scans. Complete response is absence of disease (e.g., lesions) by imaging.
Time frame: Disease response was performed at 6 and 12 weeks after the first dose of Avelumab. Patients who experience a complete response will be evaluated every 6 weeks x 3, then every 12 weeks x 3, then every 26 weeks x 2 or until disease progression,up to 3 years
Population: Four of twelve patients had evaluable pulmonary disease as assessed by CT scan.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Avelumab | Number of Patients With Pulmonary Recurrent Respiratory Papillomatosis (RPP) Who Achieve a Complete Response With Avelumab as Measured by the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 Calculated From Chest Computed Tomography (CT) Scans | 0 Participants |
Secondary
Duration of Clinical Responses to Avelumab
The duration of clinical responses to Avelumab is calculated from the protocol end of treatment endoscopic debulking to the next clinically indicated endoscopic debulking procedure.
Time frame: Disease response was performed at 6 and 12 weeks after the first dose of Avelumab. Patients who experience a complete response will be evaluated every 6 weeks x 3, then every 12 weeks x 3, then every 26 weeks x 2 or until disease progression,up to 4.5 yrs
Population: 5/12 participants were evaluable for this outcome measure.
| Arm | Measure | Value (MEAN) |
|---|---|---|
| Avelumab | Duration of Clinical Responses to Avelumab | 14.7 Months |
Secondary
Effect of Treatment With Avelumab on Voice Handicap Index-10 Score
The Voice Handicap Index-10 questionnaire (as measured by derkay score) consists of 10 questions and determines whether a participant has a voice handicap. The scoring options for each question range from 0 (for never) to 4 (for always). The total scores (combined value from all 10 questions) range from 0 - 40. Higher scores represent a worse voice handicap. Lower scores represent a less voice handicap.
Time frame: Baseline, 6 weeks, and 12 weeks after the first dose of Avelumab.
Population: Only one participant in each row contributed data in each row.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Avelumab | Effect of Treatment With Avelumab on Voice Handicap Index-10 Score | Patient 4 | 17 scores on a scale |
| Avelumab | Effect of Treatment With Avelumab on Voice Handicap Index-10 Score | Patient 11 | 18 scores on a scale |
| Avelumab | Effect of Treatment With Avelumab on Voice Handicap Index-10 Score | Patient 8 | 30 scores on a scale |
| Avelumab | Effect of Treatment With Avelumab on Voice Handicap Index-10 Score | Patient 5 | 12 scores on a scale |
| Avelumab | Effect of Treatment With Avelumab on Voice Handicap Index-10 Score | Patient 2 | 9 scores on a scale |
| Avelumab | Effect of Treatment With Avelumab on Voice Handicap Index-10 Score | Patient 6 | 19 scores on a scale |
| Avelumab | Effect of Treatment With Avelumab on Voice Handicap Index-10 Score | Patient 7 | 40 scores on a scale |
| Avelumab | Effect of Treatment With Avelumab on Voice Handicap Index-10 Score | Patient 1 | 26 scores on a scale |
| Avelumab | Effect of Treatment With Avelumab on Voice Handicap Index-10 Score | Patient 10 | 18 scores on a scale |
| Avelumab | Effect of Treatment With Avelumab on Voice Handicap Index-10 Score | Patient 3 | 40 scores on a scale |
| Avelumab | Effect of Treatment With Avelumab on Voice Handicap Index-10 Score | Patient 13 | 18 scores on a scale |
| Avelumab | Effect of Treatment With Avelumab on Voice Handicap Index-10 Score | Patient 9 | 37 scores on a scale |
| All Participants at 6 Weeks | Effect of Treatment With Avelumab on Voice Handicap Index-10 Score | Patient 6 | 0 scores on a scale |
| All Participants at 6 Weeks | Effect of Treatment With Avelumab on Voice Handicap Index-10 Score | Patient 13 | 19 scores on a scale |
| All Participants at 6 Weeks | Effect of Treatment With Avelumab on Voice Handicap Index-10 Score | Patient 1 | 22 scores on a scale |
| All Participants at 6 Weeks | Effect of Treatment With Avelumab on Voice Handicap Index-10 Score | Patient 2 | 12 scores on a scale |
| All Participants at 6 Weeks | Effect of Treatment With Avelumab on Voice Handicap Index-10 Score | Patient 3 | 37 scores on a scale |
| All Participants at 6 Weeks | Effect of Treatment With Avelumab on Voice Handicap Index-10 Score | Patient 4 | 16 scores on a scale |
| All Participants at 6 Weeks | Effect of Treatment With Avelumab on Voice Handicap Index-10 Score | Patient 5 | 2 scores on a scale |
| All Participants at 6 Weeks | Effect of Treatment With Avelumab on Voice Handicap Index-10 Score | Patient 7 | 21 scores on a scale |
| All Participants at 6 Weeks | Effect of Treatment With Avelumab on Voice Handicap Index-10 Score | Patient 8 | 35 scores on a scale |
| All Participants at 6 Weeks | Effect of Treatment With Avelumab on Voice Handicap Index-10 Score | Patient 9 | 40 scores on a scale |
| All Participants at 6 Weeks | Effect of Treatment With Avelumab on Voice Handicap Index-10 Score | Patient 10 | 11 scores on a scale |
| All Participants at 6 Weeks | Effect of Treatment With Avelumab on Voice Handicap Index-10 Score | Patient 11 | 9 scores on a scale |
| All Participants at 12 Weeks | Effect of Treatment With Avelumab on Voice Handicap Index-10 Score | Patient 1 | 23 scores on a scale |
| All Participants at 12 Weeks | Effect of Treatment With Avelumab on Voice Handicap Index-10 Score | Patient 8 | 29 scores on a scale |
| All Participants at 12 Weeks | Effect of Treatment With Avelumab on Voice Handicap Index-10 Score | Patient 3 | 38 scores on a scale |
| All Participants at 12 Weeks | Effect of Treatment With Avelumab on Voice Handicap Index-10 Score | Patient 13 | 15 scores on a scale |
| All Participants at 12 Weeks | Effect of Treatment With Avelumab on Voice Handicap Index-10 Score | Patient 9 | 40 scores on a scale |
| All Participants at 12 Weeks | Effect of Treatment With Avelumab on Voice Handicap Index-10 Score | Patient 2 | 3 scores on a scale |
| All Participants at 12 Weeks | Effect of Treatment With Avelumab on Voice Handicap Index-10 Score | Patient 11 | 0 scores on a scale |
| All Participants at 12 Weeks | Effect of Treatment With Avelumab on Voice Handicap Index-10 Score | Patient 6 | 0 scores on a scale |
| All Participants at 12 Weeks | Effect of Treatment With Avelumab on Voice Handicap Index-10 Score | Patient 5 | 1 scores on a scale |
| All Participants at 12 Weeks | Effect of Treatment With Avelumab on Voice Handicap Index-10 Score | Patient 10 | 12 scores on a scale |
| All Participants at 12 Weeks | Effect of Treatment With Avelumab on Voice Handicap Index-10 Score | Patient 7 | 18 scores on a scale |
| All Participants at 12 Weeks | Effect of Treatment With Avelumab on Voice Handicap Index-10 Score | Patient 4 | 16 scores on a scale |
Secondary
Number of Participants With Serious and Non-serious Adverse Events
Here is the count of participants with serious and non-serious adverse events assessed by the Common Terminology Criteria in Adverse Events (CTCAE v4.0). A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned.
Time frame: Date treatment consent signed to date off study, approximately 28 months and 20 days.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Avelumab | Number of Participants With Serious and Non-serious Adverse Events | 13 Participants |
Secondary
Number of Patients With Laryngotracheal Recurrent Respiratory Papillomatosis (RPP) Who Achieve a Partial Response With Avelumab as Measured by Derkay Score Calculated From Clinical Endoscopy
Partial response is assessed by flexible nasopharyngolaryngoscopy and/or tracheoscopy using the Derkay staging system if the patient does not have pulmonary disease. The Derkay is an objective score based on the number of sites and bulkiness of papillomas within the pharynx, larynx and trachea and a subjective score determined by voice and treating symptoms. Partial response is a decrease in Derkay anatomic score of 30% or greater.
Time frame: Disease response was performed at 6 and 12 weeks after the first dose of Avelumab. Patients who experience a complete response will be evaluated every 6 weeks x 3, then every 12 weeks x 3, then every 26 weeks x 2 or until disease progression,up to 3 years
Population: Nine of twelve patients had evaluable laryngotracheal disease as assessed by clinical endoscopy.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Avelumab | Number of Patients With Laryngotracheal Recurrent Respiratory Papillomatosis (RPP) Who Achieve a Partial Response With Avelumab as Measured by Derkay Score Calculated From Clinical Endoscopy | 6 Participants |
Secondary
Number of Patients With Pulmonary Recurrent Respiratory Papillomatosis (RPP) Who Achieve a Partial Response With Avelumab as Measured by the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 Calculated From Chest Computed Tomography (CT) Scans
Partial response assessed by imaging using RECIST v1.1. is defined as a ≥ 30% decrease in the sum of the longest diameters of target lesions compared with baseline.
Time frame: Disease response was performed at 6 and 12 weeks after the first dose of Avelumab. Patients who experience a complete response will be evaluated every 6 weeks x 3, then every 12 weeks x 3, then every 26 weeks x 2 or until disease progression, up to 3 year
Population: Four of twelve patients had evaluable pulmonary disease as assessed by CT scan.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Avelumab | Number of Patients With Pulmonary Recurrent Respiratory Papillomatosis (RPP) Who Achieve a Partial Response With Avelumab as Measured by the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 Calculated From Chest Computed Tomography (CT) Scans | 0 Participants |